Literature DB >> 6380574

Reaction intermediate analogues for enolase.

V E Anderson, P M Weiss, W W Cleland.   

Abstract

A number of compounds that appear to be analogues of the aci form of the normal carbanion intermediate are good inhibitors of yeast enolase. These include (3-hydroxy-2-nitropropyl)phosphonate (I), the ionized (pK = 8.1) nitronate form of which in the presence of 5 mM Mg2+ has a Ki of 6 nM, (nitroethyl)phosphonate (III) (pK = 8.5; Ki of the nitronate in the presence of 5 mM Mg2+ = 1 microM), phosphonoacetohydroxamate (IV) (pK = 10.2; Ki with saturating Mg2+ for the ionized form = 15 pM), and (phosphonoethyl)nitrolate (VII) (Ki at 1 mM Mg2+ = 14 nM). The oxime of phosphonopyruvate (VI) has a pH-independent Ki of 75 microM. I, IV, VI, and VII are slow binding inhibitors. All of these compounds are trigonal at the position analogous to C-2 of 2-phosphonoglycerate and contain a phosphono group, but a negatively charged metal ligand at the position isosteric with the hydroxyl attached to C-3 of 2-phosphoglycerate (as in IV) appears to contribute more to binding than a nitro group isosteric with the carboxyl of 2-phosphoglycerate (I and III). These data support the carbanion mechanism for enolase and suggest that the 3-hydroxyl of 2-phosphoglycerate is directly coordinated to Mg2+ prior to being eliminated to give phosphoenolpyruvate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6380574     DOI: 10.1021/bi00307a038

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

Review 2.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

3.  In silico prediction of a new lead compound targeting enolase of trypanosomatids through structure-based virtual screening and molecular dynamic studies.

Authors:  V M Vidhya; B S Lakshmi; Karthe Ponnuraj
Journal:  J Mol Model       Date:  2020-01-07       Impact factor: 1.810

4.  PcxL and HpxL are flavin-dependent, oxime-forming N-oxidases in phosphonocystoximic acid biosynthesis in Streptomyces.

Authors:  Michelle N Goettge; Joel P Cioni; Kou-San Ju; Katharina Pallitsch; William W Metcalf
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

5.  The catalytic Mn2+ sites in the enolase-inhibitor complex: crystallography, single-crystal EPR, and DFT calculations.

Authors:  Raanan Carmieli; Todd M Larsen; George H Reed; Samir Zein; Frank Neese; Daniella Goldfarb
Journal:  J Am Chem Soc       Date:  2007-03-17       Impact factor: 15.419

6.  Passenger deletions generate therapeutic vulnerabilities in cancer.

Authors:  Florian L Muller; Simona Colla; Elisa Aquilanti; Veronica E Manzo; Giannicola Genovese; Jaclyn Lee; Daniel Eisenson; Rujuta Narurkar; Pingna Deng; Luigi Nezi; Michelle A Lee; Baoli Hu; Jian Hu; Ergun Sahin; Derrick Ong; Eliot Fletcher-Sananikone; Dennis Ho; Lawrence Kwong; Cameron Brennan; Y Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

7.  SF2312 is a natural phosphonate inhibitor of enolase.

Authors:  Paul G Leonard; Nikunj Satani; David Maxwell; Yu-Hsi Lin; Naima Hammoudi; Zhenghong Peng; Federica Pisaneschi; Todd M Link; Gilbert R Lee; Duoli Sun; Basvoju A Bhanu Prasad; Maria Emilia Di Francesco; Barbara Czako; John M Asara; Y Alan Wang; William Bornmann; Ronald A DePinho; Florian L Muller
Journal:  Nat Chem Biol       Date:  2016-10-10       Impact factor: 15.040

8.  ENOblock Does Not Inhibit the Activity of the Glycolytic Enzyme Enolase.

Authors:  Nikunj Satani; Yu-Hsi Lin; Naima Hammoudi; Sudhir Raghavan; Dimitra K Georgiou; Florian L Muller
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

9.  In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically.

Authors:  Jrhau Lung; Kuan-Liang Chen; Chien-Hui Hung; Chih-Cheng Chen; Ming-Szu Hung; Yu-Ching Lin; Ching-Yuan Wu; Kuan-Der Lee; Neng-Yao Shih; Ying Huang Tsai
Journal:  Drug Des Devel Ther       Date:  2017-11-16       Impact factor: 4.162

10.  The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues.

Authors:  Federica Pisaneschi; Yu-Hsi Lin; Paul G Leonard; Nikunj Satani; Victoria C Yan; Naima Hammoudi; Sudhir Raghavan; Todd M Link; Dimitra K Georgiou; Barbara Czako; Florian L Muller
Journal:  Molecules       Date:  2019-07-09       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.